Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim. The investigators will prospectively collect clinical data and treatment outcome of patients with DLBCL who use prophylactic pegylated-filgrastim.
Diffuse Large B Cell Lymphoma|Neutropenia, Febrile
incidence of febrile neutropenia, within 30 days
incidence of chemotherapy-related adverse events other than febrile neutropenia, 4 weeks after completion of chemotherapy|Overall survival, 2 year
* Newly diagnosed DLBCL patients treated with R-CHOP chemotherapy
* Prphylactic peg-filgrastim on the day after chemotherapy